NEW YORK, NY / ACCESSWIRE / August 26, 2020 / RYAH Medtech Inc. ("RYAH" or the "Company"), announced today that it has signed a Memorandum of Understanding ("MOU") with Argos Applied Intelligence ("Argos-AI") to transform RYAH's patented AI analytics in plant-based medicine research.
The MOU sets the plan to create an initial Proof of Concept ("PoC") of a proprietary, scalable enterprise data analytics platform in plant-based medicine and other formulations. The goals involve extensive analysis and normalization of the various data pools from RYAH's applications.
The final integrated solution is expected to combine the anonymous patient use data from RYAH's IoT devices with its AI-powered analytics platform. The single, turn-key solution is further expected to be supported by machine learning and visualization tools, which can be used by hospitals, clinics, universities, and research organizations to encourage the advancement of pharmaceutical research in plant-based medicines and to be connected with potentially eligible patients for new clinical trial studies.
The details of the work for the initial PoC stage will be formalized in a definitive agreement between RYAH and Argos-AI.
"This collaboration with Argos-AI is an opportunity for RYAH to unlock new monetization strategies by accelerating our transformation of proprietary dashboards and APIs into a scalable enterprise data platform," said Gregory Wagner, CEO, RYAH Medtech Inc. "With the help of Argos-AI and yet to be announced new partners, patients will be able to connect to new clinical studies, while medical institutions can leverage RYAH IoT devices and analytics to remotely administer, monitor, and assess the resulting data on a single platform."
About RYAH Medtech, Inc.
RYAH is a big data and technology company focused on valuable predictive analysis in the global medical plant intake industry. The company manages a complete digital ecosystem leveraging both Internet of Things and Artificial Intelligence to create a dynamic data service for the medical plant industry. It is developing a suite of IoT devices, including a dry-herb vaporizer device capable of storing all plant lab results, measuring patient inhalation sessions in real-time, and capturing instant feedback for plant dose management. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant medical data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is also relevant for pharmacies, clinics, growers, dispensaries, and Licensed Processors (LPs) to monitor and manage plant strain effects on patients. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete medical plant lifecycle, from seed to consumption.
About Argos Applied-Intelligence
Argos-AI is a minority-owned South Florida firm specializing in cybersecurity workforce development, cyber data analytics, and cybersecurity services. Argos-AI leverages a network of current and former private industry, military, federal law enforcement cyber threat intelligence analysts, agents, and officers. Argos-AI and its partners pursue game-changing advances in machine learning and artificial intelligence to mitigate cyber risk. Our focus combines advances in Data Operations (DataOps) with innovations in machine learning, natural language processing, and human-computer-data interaction to solve some of the toughest challenges in cyber risk management and to directly inform Argos-AI's skills, research, and services development and delivery.
RYAH Medtech Inc Contacts:
+1 917 210 0543
Argos Applied-Intelligence Contacts:
Certain statements contained in this press release constitute "forward-looking information" as such term is defined in applicable Canadian securities legislation and United States rules and regulation. The words "may", "would", "could", "should", "potential", "will", "seek", "intend", "plan", "anticipate", "believe", "estimate", "expect" and similar expressions as they relate to the Company are intended to identify forward-looking information. All statements other than statements of historical fact may be forward-looking information. Such statements reflect the Company's current views and intentions with respect to future events, and current information available to the Company, and are subject to certain risks, uncertainties, and assumptions. Many factors could cause the actual results, performance, or achievements that may be expressed or implied by such forward-looking information to vary from those described herein should one or more of these risks or uncertainties materialize. Should any factor affect the Company in an unexpected manner, or should assumptions underlying the forward-looking information prove incorrect, the actual results or events may differ materially from the results or events predicted. Any such forward-looking information is expressly qualified in its entirety by this cautionary statement. Moreover, the Company does not assume responsibility for the accuracy or completeness of such forward-looking information. The forward-looking information included in this press release is made as of the date of this press release, and the Company undertakes no obligation to publicly update or revise any forward-looking information, other than as required by applicable law.
SOURCE: RYAH Medtech Inc.